Author details

Full Name

Lynda Chin

Affiliation

ORCID

Career Start Year

1984

Papers

208

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36821804	A Study Design to Harmonize Patient-Reported Outcomes Across Data Sets.		2023
34419532	Preface.		2021
34062153	A digital highway for data fluidity and data equity in precision medicine.		2021
32897732	Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.	JCO Glob Oncol	2020
30446581	Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care.	Oncologist	2019
29686388	Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma.	Nat Genet	2018
28178232	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.	Nature	2017
28819565	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.	NPJ Genom Med	2017
28455392	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.	Cancer Discov	2017
28445736	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression.	Cell Rep	2017
28698296	PRKCI promotes immune suppression in ovarian cancer.	Genes Dev	2017
28514651	Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma.	Cell Rep	2017
29073105	PAF promotes stemness and radioresistance of glioma stem cells.	Proc Natl Acad Sci U S A	2017
28251903	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.	Sci Transl Med	2017
27863244	Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth.	Cell	2016
27301722	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.	Cancer Discov	2016
26884185	Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.	Proc Natl Acad Sci U S A	2016
27141370	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.	Oncoimmunology	2016
27049164	Genome engineering - Matching supply with demand.	Cell Cycle	2016
27320920	InÂ Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.	Cell Rep	2016
26854237	Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair.	Cell Reports	2016
26105212	Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.	Br J Haematol	2016
26701088	Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.	Cancer Discov	2016
27801678	Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.	J Clin Invest	2016
27515299	MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.	Clin Cancer Res	2016
26061751	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.	N Engl J Med	2015
28843279	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.	Cancer Cell	2015
28741560	Cancer Genomics in Clinical Context.	Trends Cancer	2015
25801490	Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission.	Am J Hematol	2015
25838542	miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.	Genes and Development	2015
25705882	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.	J Clin Invest	2015
25583766	Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.	J Natl Compr Canc Netw	2015
25650244	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.	Genome Res	2015
25965571	Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.	Cancer Cell	2015
26392354	HiCPlotter integrates genomic data with interaction matrices.		2015
26551685	Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.	J Clin Invest	2015
26153864	Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer.	Nature	2015
26450788	Dual Roles of RNF2 in Melanoma Progression.	Cancer Discov	2015
26193637	Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.	J Clin Invest	2015
25056119	The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.	Cancer Res	2014
25260652	Polygenic in vivo validation of cancer mutations using transposons.	Genome Biol	2014
24453001	Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions.	Cancer Res	2014
24398677	Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.	J Biol Chem	2014
23435427	HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome.	Oncogene	2014
24954535	Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.	Cell	2014
24632752	MTSS1 is a metastasis driver in a subset of human melanomas.	Nat Commun	2014
24856586	Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.	Cancer Cell	2014
23657389	Recapitulating human cancer in a mouse.	Nat Biotechnol	2013
24157732	Semiconductor-based DNA sequencing of histone modification states.	Nat Commun	2013
24148783	The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.	Genome Biol	2013